Back to Search Start Over

IDENTIFICATION AND DIAGNOSIS OF POSSIBLE MUTATIONS IN HUMAN P-53 LYMPHOCYTES.

Authors :
Delia, Nica-Badea
Tiberiu, Tataru
Cristian, Marinas Marius
Vlad, Băleanu
Aurelian, Udriștioiu
Paula, Tataru
Tiberiu Stefanita, Tenea Cojan
Source :
Pharmacophore. 2023, Vol. 14 Issue 6, p52-58. 7p.
Publication Year :
2023

Abstract

This study looked at a few confirmed cases of chronic lymphocytic leukemia (CLL) that may have had mutations in the human B lymphocyte genome's P-53 gene. The ELISA technique was used to determine the frequency of p-53 protein expression in twenty CLL patients undergoing evaluation in stages II–III / IV. In 17 of the 20 cases, the average amounts of p-53 proteins were found to be 16.76 μg/dl, with a probability index of p = 0.034 and a CV of 0.5%. It was discovered that as the illness progressed, the proportion of p-53 positive isoform proteins rose above normal. The percentage was 15% ± 2 in stages 1-2 and 100% in stages 3-4. Recent studies have shown that the p-53 protein inhibits protein kinase B, the AMPK protein, and the mTOR complex, hence mediating genes that trigger autophagy and stimulating autophagy. One potential use of the p-53 protein's role in cancer cell autophagy is the development of a novel anti-cancer medicinal approach. When a patient develops resistance to the initial line of treatment, the ELISA approach has shown to be an invaluable prognostic tool for CLL, enabling the administration of customized medication. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
22295402
Volume :
14
Issue :
6
Database :
Academic Search Index
Journal :
Pharmacophore
Publication Type :
Academic Journal
Accession number :
175350111
Full Text :
https://doi.org/10.51847/z8kBl0vAMH